OasisLMS

Cases in Precision Oncology: Highlights from the 2025 ClinGen Somatic Cancer and VICC Virtual Molecular Tumor Board Case Series

Tuesday, January 27, 2026

11:00am-12:00pm ET

www.acmgeducation.net

1.0 AMA PRA Category 1 Credits™, P.A.C.E.® - Educational Credits Claim by February 27

This CME Case Series reflects the work of molecular tumor boards by featuring an interdisciplinary discussion of cases that are subject to comprehensive molecular characterization using a variety of advanced technologies. The molecular characterization of tumor samples ranges from methods on the genomic level to recent advances in proteomics. The field is advancing rapidly, and more and more approaches will translate from basic research to clinical care. In this session, we will summarize the variety of methods described in previous virtual molecular tumor boards and highlight the most interesting cases from 2025. In addition, we will give an outlook on topics to come in 2026.

Target Audience

All medical and healthcare professionals and researchers interested in understanding cancer genomic testing and somatic and germline variant interpretation methods. This series is presented as a collaboration between ClinGen Somatic, VICC, and ACMG consortia.

Agenda

Presentations followed by live Q&A. 

Learning Objectives

At the conclusion of this session, participants should be able to:

•  Name three different types of molecular characterization methods.
• Explain how different types of results can be integrated to benefit a cancer patient.
• Describe one major challenge in precision oncology.

	Manuela Benary, PhD Bioinformatician Charité – Universitätsmedizin Berlin, Berlin, Germany
	Beth Pitel, MS Clinical Variant Scientist – Oncology Assistant Professor of Laboratory Medicine and Pathology Mayo Clinic
	Jason Saliba, PhD Senior Scientist at Washington University School of Medicine in St. Louis

Planning Committee:
Beth Pitel, MS, CG(ASCP)
Gordana Raca, MD, PhD, FACMG
Manuela Benary, PhD
Jason Saliba, PhD

Staff:
Jane Radford, MHA, CHCP
Claudia Barnett

AMA PRA Category 1 Credit^TM, ASCLS P.A.C.E.^®

Accreditation

The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation
The American College of Medical Genetics and Genomics designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Claiming your Educational Credits

Complete the activity and carefully complete the evaluation form. The deadline to claim educational credits is within 30 days from the date of the activity. Educational credit requests after this date will not be accepted.

Learner Data Consent

ACMG Education reports learner data to respective agency boards and you will be asked for consent during the evaluation process. Your compliance with deadlines and completing evaluations are part of the process in meeting learner needs and ACMG’s education mission.

Technical Support:
You can reach us by email at education@acmg.net or call 301-718-9603.
Support Center Hours: Monday – Friday, 9:00 AM – 5:00 PM Eastern Time.

Accredited Continuing Education Financial Disclosure

The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.

ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

ACMG Education Policies

Please review the policies below regarding the ACMG Education program

• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclaimer

ACMG educational programs are designed primarily as an educational tool for healthcare professionals who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare professional should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.

Questions regarding CE credit should be directed to education@acmg.net